In pivotal trials, weekly semaglutide produced roughly 1415% body-weight reduction at 68 weeks (STEP 1, NEJM 2021), and tirzepatide a dual GIP/GLP-1 co-agonist reached 1822% at one year (SURMOUNT-1, NEJM 2022)
Phase 2 clinical research published in 2023 documented metabolic effects that exceeded those reported for any prior incretin agonist
Try to eat small, frequent meals even if you dont feel very hungry
A Clinically Guided, Science-Based Approach to Weight Loss Unlike older stimulant-based weight loss medications, GLP-1 injection treatments work by targeting metabolic pathways that help regulate appetite and fullness
Healthcare providers need to overcome barriers related to the shortage and mitigate undesired negative consequences from an inability of patients with type 2 diabetes mellitus to obtain GLP-1 receptor agonist therapies amid this global access challenge
You should only consider these medications in collaboration with a pediatrician or pediatric endocrinologist and never obtain them yourself online
